Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Cancer cells exhibit more dependence on iron and enhanced sensitivity to ferroptosis than normal cells. Quercetin is known to possess anti‐cancer effects, but the molecular mechanism is largely unknown. In this study, we aimed to investigate the involvement of lysosome function and ferroptosis to further explore the anti‐cancer potential of Quercetin.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approaches</h3><p>We utilized MTT assay and DNA content analysis to evaluate the cytotoxicity; colony formation assay to investigate cell proliferation; flow cytometry and confocal microscopy to detect lysosomal acidification and protease enzyme activity; Western blotting, cell subfraction, RT‐PCR and siRNA transfection were used to establish molecular mechanisms of action.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>Quercetin is able to promote p53‐independent cell death in various cancer cell lines. Although Quercetin induces autophagy, genetic silencing of Atg7 fails to affect Quercetin‐induced cell death. In contrast, both lysosome inhibitors and TFEB knockdown can prevent Quercetin‐induced cell death, suggesting the involvement of lysosome. Next, Quercetin is found to induce lysosomal activation sequentially through TFEB nuclear translocation and transcriptional activation of lysosomal genes. Notably, Quercetin promotes lysosome‐dependent ferritin degradation and free iron release. This action and Quercetin‐induced ROS generation synergistically result in lipid peroxidation and ferroptosis. Furthermore, we provided evidence that Bid may link ferroptosis with apoptosis to cause cell death.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion and Implications</h3><p>In summary, our study demonstrates that Quercetin induces TFEB‐mediated lysosome activation and then promotes ferritin degradation, which consequently leads to ferroptosis and Bid‐involved apoptosis. Results from this study may expand our current knowledge about the mechanism of Quercetin in anti‐cancer therapy.</p></section>

The potential interplay between G-quadruplex and p53: their roles in regulation of ferroptosis in cancer

p53: A double-edged sword in tumor ferroptosis

Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy

Pioneering the future of cancer therapy: Deciphering the p53-ferroptosis nexus for precision medicine

p53 in ferroptosis regulation: the new weapon for the old guardian

Ferroptosis and the bidirectional regulatory factor p53

Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53

Ferroptosis as a p53-mediated activity during tumour suppression

The function and mechanism of ferroptosis in cancer

Quercetin induces p53‐independent cancer cell death through lysosome activation by the transcription factor EB and Reactive Oxygen Species‐dependent ferroptosis

Understanding the mechanistic regulation of ferroptosis in cancer: the gene matters

Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells

Ferroptosis As a Mechanism to Mediate P53 Function in Tumor Radiosensitivity

Regulation of Ferroptosis Pathway by Ubiquitination

Ferroptosis in liver diseases: Fundamental mechanism and clinical implications

Potential Roles and Mechanisms of Curcumin and its Derivatives in the Regulation of Ferroptosis

Deciphering the link: ferroptosis and its role in glioma

The Potential Role of Non-coding RNAs in Regulating Ferroptosis in Cancer: Mechanisms and Application Prospects

Ferroptosis in tumors and its relationship to other programmed cell death: role of non-coding RNAs

Molecular mechanisms of ferroptosis and its role in cancer therapy

Regulation of ferroptosis by PI3K/Akt signaling pathway: a promising therapeutic axis in cancer